CAMP4 Therapeutics (CAMP) Reiterated at Overweight by Cantor Fitzgerald After Analyst Day

September 29, 2026 7:18 AM

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $7.00 price target on CAMP4 Therapeutics Corp (NASDAQ: CAMP).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found